Shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) rose 1% during trading on Thursday . The company traded as high as $1.06 and last traded at $1.05. Approximately 10,264 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.04.
Qualigen Therapeutics Stock Performance
The company has a market capitalization of $1.78 million, a P/E ratio of -0.14 and a beta of 0.24. The firm’s fifty day moving average is $1.28 and its 200-day moving average is $1.53.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Featured Stories
- Five stocks we like better than Qualigen Therapeutics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
